Hesperidin prevents liver fibrosis in rats by decreasing the expression of nuclear factor-κB, transforming growth factor-β and connective tissue growth factor

Pharmacology

Volumn 94, Issue , 2014, Pages 80-89

  Pérez Vargas, J Eliuth ^a   Zarco, Natanael ^a   Shibayama, Mineko ^a   Segovia, José ^a   Tsutsumi, Víctor ^a   Muriel, Pablo ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Carbon tetrachloride; Fibrosis; Hesperidin; Nuclear factor B; Oxidative stress; Profibrotic cytokines; Proinflammatory cytokines

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBON TETRACHLORIDE; CONNECTIVE TISSUE GROWTH FACTOR; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; HESPERIDIN; HYDROXYPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; TRANSFORMING GROWTH FACTOR BETA; ANTIOXIDANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL LIVER CIRRHOSIS; FIBRINOLYSIS; GLYCOGEN ANALYSIS; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOREACTIVITY; LIPID LIVER LEVEL; LIPID PEROXIDATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NECROSIS; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CARBON TETRACHLORIDE; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HESPERIDIN; LIPID PEROXIDATION; LIVER CIRRHOSIS; MALE; NECROSIS; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA;

EID: 84908565818     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000366206     Document Type: Article

References (37)

1. Majumdar S, Srirangam R: Solubility, stability, physicochemical characteristics and in vitro ocular tissue permeability of hesperidin: a natural bioflavonoid. Pharm Res 2009; 26: 1217-1225.
2. Garg A, et al: Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 2001; 15: 655-669.
3. Chen M, et al: Protective effects of hesperidin against oxidative stress of tert-butyl hydroperoxide in human hepatocytes. Food Chem Toxicol 2010; 48: 2980-2987.
4. Hirata A, et al: Kinetics of radical-scavenging activity of hesperetin and hesperidin and their inhibitory activity on COX-2 expression. Anticancer Res 2005; 25: 3367-3374.
5. Lee KH, et al: The inhibitory effect of hesperidin on tumor cell invasiveness occurs via suppression of activator protein 1 and nuclear factor-κB in human hepatocellular carcinoma cells. Toxicol Lett 2010; 194: 42-49.
6. Ghorbani A, et al: The citrus flavonoid hesperidin induces p53 and inhibits NF-κB activation in order to trigger apoptosis in NALM-6 cells: involvement of PPARγ-dependent mechanism. Eur J Nutr 2012; 51: 39-46.
7. Nazari M, et al: Inactivation of nuclear factor-κB by citrus flavanone hesperidin contributes to apoptosis and chemo-sensitizing effect in Ramos cells. Eur J Pharmacol 2011; 650: 526-533.
8. Muriel P: NF-κB in liver diseases: a target for drug therapy. J Appl Toxicol 2009; 29: 91-100.
9. Perez Tamayo R: Is cirrhosis of the liver experimentally produced by CCl 4 an adequate model of human cirrhosis? Hepatology 1983; 3: 112-120.
10. Reitman S, Frankel S: A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28: 56-63.
11. Glossmann H, Neville DM: γ-Glutam yl transferase in kidney brush border membranes. FEBS Lett 1972; 19: 340-344.
12. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
13. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 1976; 72: 248-254.
14. Hissin PJ, Hilf R: A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976; 74: 214-226.
15. Seifter S, Dayton S, et al: The estimation of glycogen with the anthrone reagent. Arch Biochem 1950; 25: 191-200.
16. Prockop DJ, Udenfriend S: A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1960; 1: 228-239.
17. Muriel P, Deheza R: Fibrosis and glycogen stores depletion induced by prolonged biliary obstruction in the rat are ameliorated by metadoxine. Liver Int 2003; 23: 262-268.
18. Goldring JP: Protein quantification methods to determine protein concentration prior to electrophoresis. Methods Mol Biol 2012; 869: 29-35.
19. Segovia J, Vergara P, Brenner M: Differentiation-dependent expression of transgenes in engineered astrocyte cell lines. Neurosci Lett 1998; 242: 172-176.
20. Bettinger BT, Gilbert DM, Amberg DC: Actin up in the nucleus. Nat Rev Mol Cell Biol 2004; 5: 410-415.
21. Tirkey N, Pilkhwal S, Kuhad A, Chopra K: Hesperidin, a citrus bioflavonoid, decreases the oxidative stress produced by carbon tetrachloride in rat liver and kidney. BMC Pharmacol 2005; 5: 2.
22. Kim WR, et al: Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008; 47: 1363-1370.
23. Linder H: The significance of transaminase determination for the evaluation of therapeutic success in liver diseases (in German). Munch Med Wochenschr 1959; 101: 1782-1786.
24. Krahenbuhl S, Weber FL Jr, Brass EP: Decreased hepatic glycogen content and accelerated response to starvation in rats with carbon tetrachloride-induced cirrhosis. Hepatology 1991; 14: 1189-1195.
25. Muriel P, Moreno MG: Effects of silymarin and vitamins E and C on liver damage induced by prolonged biliary obstruction in the rat. Basic Clin Pharmacol Toxicol 2004; 94: 99-104.
26. Muriel P: Peroxidation of lipids and liver damage; in Baskin SI, Salem H (eds): Oxidants, Antioxidants, and Free Radicals. Washington, Taylor & Francis, 1997, pp 237-257.
27. Hernandez-Gea V, Friedman SL: Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456.
28. Gressner AM, Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99.
29. Meyer C, Meindl-Beinker NM, Dooley S: TGF-β signaling in alcohol induced hepatic injury. Front Biosci 2010; 15: 740-749.
30. Iredale JP: Matrix turnover in fibrogenesis. Hepatogastroenterology 1996; 43: 56-71.
31. Gressner AM, et al: TGF-β-mediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes. J Hepatol 1997; 26: 1079-1092.
32. Gressner OA, et al: Activation of TGF-β within cultured hepatocytes and in liver injury leads to intracrine signaling with expression of connective tissue growth factor. J Cell Mol Med 2008; 12: 2717-2730.
33. Weng HL, et al: Profibrogenic transforming growth factor-β/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology 2007; 46: 1257-1270.
34. Tilg AK, Moschen AR: How to modulate inflammatory cytokines in liver diseases. Liver Int 2006; 1029-1039.
35. Le Moine O, et al: Interleukin-10 and liver diseases. Acta Gastroenterol Belg 1999; 62: 1-8.
36. Huang YH, et al: Therapeutic effect of interleukin-10 on CCl 4-induced hepatic fibrosis in rats. World J Gastroenterol 2006; 12: 1386-1391.
37. Muriel P: Cytokines in liver diseases; in Sahu SC (ed): Hepatotoxicity: From Genomics to in vitro and in vivo Models. Chichester, John Wiley, 2007, pp 371-389.